Not blinding sampling times [Bioanalytics]
❝ Even if substantial carry-over is not apparent in method validation (which would call for injecting mobile phase between samples), it exists. The EMA’s GL tells us [...]
Going by that guideline, will it be safe to say that the converse it also true. That is:
If it appears there is no carry-over, study samples should be randomised
Well, just as you said, carryover is always very likely. Thus complete randomisation will not be the reasonable path to follow.
Thanks guys, at least I am glad I let my thoughts out and not get drowned in them.